The present invention relates to novel benzodiazepine compounds exhibiting
RXR-antagonist efficacy, for delaying progression of, preventing or
treating a condition or disease being associated with RXR-antagonism, in
particular selected from diabetes, complication of diabetes such as
retinopathy, nephropathy, neuropathy, and hyperlipidemia, obesity,
dyslipidemia, and osteoporosis.